Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Friday 13 November 2015 4:57 pm

Scientists have found a way of using humans’ own cells to target cancer

By: Sarah Spickernell

Add as a preferred source on Google

It's now possible to turn white blood cells into cancer killers, capable of tracking down and destroying the disease just as it enters its most dangerous phase.

By experimenting on mice, researchers at Cornell University in the US found that when they attached a specific protein called the TRAIL protein (Tumour necrosis factor Related Apoptosis-Inducing Ligand) to white cells found in the lymph nodes, the cells suddenly gained “super natural killer cell” qualities.

The reason why this is such a major step is that the lymph nodes, where the white blood cells are located, is also where cancer cells begin metastasis – the process by which cancer starts to spread between organs of the body. Once metastasis has taken place, it becomes far less likely that treatment will work.

Read more: World Cancer Day 2015: Why we should remain positive in the face of growing risk

"In our research, we use nanoparticles – the liposomes we have created with TRAIL protein – and attach them to natural killer cells, to create what we call 'super natural killer cells' and then these completely eliminate lymph node metastases in mice," said Michael King, lead researcher. "We want to see lymph node metastasis become a thing of the past.”

In the study, they found that when the white blood cells had the protein attached, they were easily able to find the cancer cells pre-metastasis and induce apoptosis – the self-destruction and disintegration of the cells. This stops the spread happening any further.

Finding a way to target these cells early on is crucial for the protection of humans against cancer – between 29 and 37 per cent of patients with lung, breast and bowel cancers currently have metastasis taking place in their lymph nodes when they are diagnosed with the disease.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Trending Articles

  • Citroën 2CV returns as a £13,000 electric car, and the timing is no accident

  • James Watt offers to buy back Brewdog

  • Bank of England warns Burnham of UK economy’s ‘big issue’

  • The former African gold miner taking on the billionaire Issa brothers

  • Rachel Reeves to unveil next steps for ring-fencing reform at Mansion House

More from City PM

  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • morph Launches the World’s First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Dr Mom Hand Unveils Phyto-Resonance®

    Business Wire
  • StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide

    Business Wire
  • People named Mark called upon to raise money at London charity golf day

    Sport Business
    Breaking news concept with digital globe and newspaper headlines on a blue background, representing global journalism.
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook